A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma

Trial Profile

A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Jul 2018

At a glance

  • Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Registrational
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 23 Jul 2018 Planned End Date changed from 18 Apr 2019 to 8 Apr 2019.
    • 08 Mar 2018 Planned End Date changed from 27 May 2019 to 18 Apr 2019.
    • 08 Mar 2018 Planned primary completion date changed from 6 Nov 2018 to 18 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top